UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations

Goyanes, A; Hatton, GB; Merchant, HA; Basit, AW; (2015) Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations. Int J Pharm , 484 (1-2) 103 - 108. 10.1016/j.ijpharm.2015.02.051. Green open access

[thumbnail of Basit.1462647_5-ASA.pdf]
Preview
PDF
Basit.1462647_5-ASA.pdf

Download (165kB)

Abstract

The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative colitis (UC), a disease for which many commercial modified-release products have been developed with the aim of providing targeted gastrointestinal release. The release profiles of five of these commercial formulations were evaluated in bicarbonate buffer using a novel dissolution model that mimics the dynamic conditions of the gastrointestinal tract. Monolithic and multi-particulate mesalazine formulations with pH-dependent and/or independent release mechanisms were evaluated (Asacol(®) 800, Octasa(®), Mezavant(®) XL, Salofalk(®), Pentasa(®)), and each of the products displayed a distinctive dissolution profile. The dissolution results for Mezavant(®) XL (Lialda(®)) (lag time 290min) demonstrated good correlation with previously reported in vivo disintegration times assessed by gamma-scintigraphy in humans. Octasa(®) showed a similar lag time to Mezavant(®) XL. Drug release from Asacol(®) 800 (Asacol(®) HD) showed a wide standard deviation, reflecting the great variability in vivo. Salofalk(®) displayed both delayed release and extended release characteristics. Pentasa(®) released more than 50% of its drug load in the stomach compartment of the model, which is attributed to the absence of a gastro-resistant coating in this product. The new dissolution method provided a realistic and discriminative in vitro assessment of mesalazine release from different formulations. These results demonstrate that this strategy can be used to predict intestinal release behaviour, and potentially aid the rational design of products developed to target different sites of the gut.

Type: Article
Title: Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations
Location: Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ijpharm.2015.02.051
Publisher version: http://dx.doi.org/10.1016/j.ijpharm.2015.02.051
Language: English
Additional information: Copyright © 2015 Elsevier B.V. All rights reserved.
Keywords: 5-ASA, 5-Aminosalicylic acid, Biorelevant dissolution, Colonic delivery, Enteric coatings, Physiological bicarbonate buffers
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics
URI: https://discovery.ucl.ac.uk/id/eprint/1462647
Downloads since deposit
1,744Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item